Early efforts to exploit MAGE proteins in cancer therapy have focussed on immunotherapeutic approaches, culminating in two phase III clinical trials of a recombinant MAGE-A3 protein vaccine in melanoma and NSCLC [21]. The gene discussed is MAGEA3; the disease is cancer.